<- Go Home
OKYO Pharma Limited
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Market Cap
$84.4M
Volume
114.3K
Cash and Equivalents
$1.6M
EBITDA
-$7.1M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$4.8M
Profit Margin
N/A
52 Week High
$3.35
52 Week Low
$0.90
Dividend
N/A
Price / Book Value
-14.57
Price / Earnings
-18.83
Price / Tangible Book Value
-14.57
Enterprise Value
$82.8M
Enterprise Value / EBITDA
-11.68
Operating Income
-$7.1M
Return on Equity
82.36%
Return on Assets
-169.87
Cash and Short Term Investments
$1.6M
Debt
N/A
Equity
-$5.5M
Revenue
N/A
Unlevered FCF
-$2.2M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium